JTJennifer K. Trittmann

Jennifer K. Trittmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jennifer K. Trittmann has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Yi Jin

    Pulmonary Hypertension Group, Center for Perinatal Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, Ohio, United States

    6 shared publications
  • Hanadi Almazroue

    Pulmonary Hypertension Group, Center for Perinatal Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, Ohio, United States

    5 shared publications
  • Leif D. Nelin

    Center for Perinatal Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, USA

    5 shared publications
  • Leif D. Nelin

    Comprehensive Center for Bronchopulmonary Dysplasia, Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University, Columbus, USA

    4 shared publications
  • Avante D. Milton

    Pulmonary Hypertension Group, Center for Perinatal Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, Ohio, United States

    2 shared publications
  • Bernadette Chen

    Pulmonary Hypertension Group, Center for Perinatal Research, The Ohio State University, Columbus, Ohio

    2 shared publications

Latest Publications

  • Human pulmonary microvascular endothelial cell DDAH1-mediated nitric oxide production promotes pulmonary smooth muscle cell apoptosis in co-culture

    by Hanadi Almazroue, Yi Jin, Leif D. Nelin, John C. Barba, Avante D. Milton, Jennifer K. Trittmann

    BPD-PH is characterized by vascular remodeling. NO is an apoptotic mediator made in the pulmonary endothelium by eNOS. ADMA is an endogenous eNOS inhibitor metabolized by DDAH1. EC-DDAH1 overexpression resulted in greater cleaved caspase-3 and caspase-8 protein expression and lower viable cell numbers in co-cultured SMC. After NO sequestration, SMC viable cell numbers partially recovered despite EC-DDAH1 overexpression. EC-DDAH1-mediated NO production positively regulates SMC apoptosis, which may prevent/attenuate aberrant pulmonary vascular proliferation/remodeling in BPD-PH.


  • PATET ratio by Doppler echocardiography: noninvasive detection of pediatric pulmonary arterial hypertension

    by Jennifer K. Trittmann, Hanadi Almazroue, Leif D. Nelin, Terri A. Shaffer, Charanda R. Celestine, Henry W. Green, Raphael A. Malbrue

    Pulmonary artery acceleration time (PAT) and PAT: ejection time (PATET) ratio are echocardiographic measurements of pulmonary arterial hypertension (PAH). These noninvasive quantitative measurements are ideal to follow longitudinally through the clinical course of PAH, especially as it relates to the need for and/or response to treatment. This review article focuses on the current literature of PATET measurement for infants and children as it relates to the shortening of the PATET ratio in PAH. At the same time, further development of PATET as an outcome measure for PAH in preclinical models, particularly mice, such that the field can move forward to human clinical studies that are both safe and effective. Here, we present what is known about PATET in infants and children and discuss what is known in preclinical models with particular emphasis on neonatal mouse models. In both animal models and human disease, PATET allows for longitudinal measurements in the same individual, leading to more precise determinations of disease/model progression and/or response to therapy. Impact PATET ratio is a quantitative measurement by a noninvasive technique, Doppler echocardiography, providing clinicians a more precise/accurate, safe, and longitudinal assessment of pediatric PAH. We present a brief history/state of the art of PATET ratio to predict PAH in adults, children, infants, and fetuses, as well as in small animal models of PAH. In a preliminary study, PATET shortened by 18% during acute hypoxic exposure compared to pre-hypoxia. Studies are needed to establish PATET, especially in mouse models of disease, such as bronchopulmonary, as a routine measure of PAH.


  • DDAH1 SNP rs480414 that protects against the development of pulmonary hypertension in bronchopulmonary dysplasia results in lower nitric oxide production in neonatal cord blood-derived lymphoblastoid cell lines

    by Avante D. Milton, Hanadi Almazroue, Yi Jin, Gloria Zender, Jennifer K. Trittmann

    BACKGROUND: Bronchopulmonary dysplasia (BPD) is chronic lung disease of prematurity and pulmonary hypertension (PH) is a major contributor to morbidity and mortality in BPD patients. Nitric oxide (NO) is a vasodilator and apoptotic mediator made by NO synthase (NOS). NOS is inhibited by asymmetric dimethylarginine (ADMA), and dimethylarginine dimethylaminohydrolase (DDAH) hydrolyzes ADMA. Previously, in a BPD patient cohort, we identified single nucleotide polymorphism (SNP) DDAH1 rs480414 ( G > A) that was protective against developing PH. This study aims to determine functional consequences of the DDAH1 SNP in lymphoblastoid cell lines (LCLs) derived from neonatal cord blood. We tested the hypothesis that DDAH1 SNP (AA) results in DDAH1 gain of function, leading to greater NO-mediated apoptosis compared to DDAH1 wild-type (GG) in LCLs. METHODS: LCLs were analyzed by Western blot (DDAH1, cleaved and total caspase-3 and -8, and β-actin), and RT-PCR (DDAH1, iNOS). Cell media assayed for nitrites with chemiluminescence NO analyzer, and conversion of ADMA to L-citrulline was measured by spectrophotometry. RESULTS: LCLs with DDAH1 SNP had similar levels of DDAH1 protein and mRNA expression, as well as DDAH activity, compared to DDAH1 WT LCLs. There were also no changes in cleaved caspase-3 and -8 protein levels. LCLs with DDAH1 SNP had similar iNOS mRNA expression. Nitrite levels in media were lower for DDAH1 SNP LCLs compared to DDAH1 WT LCLs ( p < 0.05). CONCLUSION: Contrary to our hypothesis, we found that NO production was lower in DDAH1 SNP LCLs, indicative of a loss of function phenotype.


  • Differential effects of the Src family tyrosine kinases Yes and Fyn on lipopolysaccharide-induced lung injury in mice

    by Jennifer K. Trittmann, Yi Jin, Yusen Liu, Leif D. Nelin

    Endothelial cell apoptosis is an early event in the development of acute lung injury (ALI). We have previously found that the Src family tyrosine kinase (STK) Yes activates caspase-3, whereas the STK Fyn inhibits caspase-3 activation in cultured pulmonary endothelial cells. We hypothesized that deficiency in Yes or Fyn in mice would have differential effects on lipopolysaccharide (LPS)-induced ALI. Mice were treated with LPS (10 mg/kg ip) for 24 h. Histological evidence of lung injury was greater in LPS-treated wild-type mice than in vehicle-treated wild-type mice, and the LPS-induced histological evidence of lung injury was attenuated in yes−/− mice and enhanced in fyn−/− mice. In wild-type or fyn−/− mice, LPS resulted in greater lung wet-to-dry weight ratios than in controls, whereas in yes−/− mice lung, wet-to-dry weight was similar between LPS and controls. LPS-exposed fyn−/− mice had greater respiratory system resistance and lower respiratory system compliance than did LPS-exposed wild-type mice. TUNEL positive cells in the lung following LPS treatment were greater in the fyn−/− mice and lower in the yes−/− mice compared with that in the wild-type mice. Following LPS treatment lung protein levels of PECAM-1 were lower in fyn−/− mice than in controls or yes−/− mice. LPS treatment increased cleaved caspase-3 protein levels in wild-type mice, whereas LPS-induced caspase-3 activation was attenuated in yes−/− mice and enhanced in fyn−/− mice. These results indicate that LPS-induced ALI is positively mediated via Yes-related mechanisms and negatively mediated by Fyn-related mechanisms.


  • Open Access

    Keratin 1: A negative regulator of inflammation and potential treatment for pulmonary arterial hypertension

    by Jennifer K. Trittmann

    This study by Zhang et al. entitled “Keratin 1 attenuates hypoxic pulmonary artery hypertension through suppressing pulmonary artery media smooth muscle expansion” is presented in a recent edition of Acta Physiologica [1]. Leading up to this research were at least three key ideas: 1) that keratin 1 (Krt1) is considered the gatekeeper of the skin’s innate immune response for its important regulatory role of both local and systemic inflammation [2], 2) that inflammation is central to the pathogenesis of pulmonary arterial hypertension (PAH) [3], and 3) that keratins can promote apoptosis of smooth muscle cells derived from human atherosclerotic lesions [4].


  • Single nucleotide polymorphisms in the dual specificity phosphatase genes and risk of necrotizing enterocolitis in premature infant

    by M.M. Talavera, Y. Jin, E.J. Zmuda, J. Frick, Y. Liu, K.L. McBride, L.D. Nelin, J.K. Trittmann

    BACKGROUND: Differences in the susceptibility of preterm infants to develop necrotizing enterocolitis (NEC) implicate potential genetic differences in response to the inflammatory stimuli leading to NEC. Dual specificity phosphatases (DUSPs) are a key suppressor pathway of the mitogen-activated protein kinase (MAPK) pro-inflammatory signaling pathway. We hypothesized that inherited single nucleotide polymorphisms (SNPs) in DUSP genes contribute to NEC susceptibility in premature infants. METHODS: Patients admitted between 2010 and 2015 born at < 32 weeks GA and≤1,500 g BW with stage II+NEC (cases; n = 50) and age, weight-matched controls ( n = 38) were included. Blood samples were collected for DNA isolation. Agena Mass Array assay was used to examine 31 SNPs in 9 different DUSP genes. Calculated minor allele frequencies (MAF) for cases and controls were compared using χ2 and logistic regression. RESULTS: The presence of the rs704074 SNP was associated with a 48% decreased risk of developing NEC (OR 0.52; 95% CI 0.27– 1.01, p = 0.04). The odds of surgical NEC decreased by 78% (OR 0.22; 95% CI 0.06– 0.84, p = 0.027) for each copy of rs704074/G allele in patients with NEC. CONCLUSION: In this small single-center pilot study, DUSP-6 SNP (rs704074) was associated with a lower risk of developing NEC and surgical NEC, the most severe form of NEC, in preterm infants.


  • Dual-specificity phosphatase (DUSP) genetic variants predict pulmonary hypertension in patients with bronchopulmonary dysplasia

    by Lauren L. Chen, Erik J. Zmuda, Maria M. Talavera, Jessica Frick, Guy N. Brock, Yusen Liu, Mark A. Klebanoff, Jennifer K. Trittmann

    Pulmonary hypertension (PH) in patients with bronchopulmonary dysplasia (BPD) results from vasoconstriction and/or vascular remodeling, which can be regulated by mitogen-activated protein kinases (MAPKs). MAPKs are deactivated by dual-specificity phosphatases (DUSPs). We hypothesized that single-nucleotide polymorphisms (SNPs) in DUSP genes could be used to predict PH in BPD. Preterm infants diagnosed with BPD (n = 188) were studied. PH was defined by echocardiographic criteria. Genomic DNA isolated from patient blood samples was analyzed for 31 SNPs in DUSP genes. Clinical characteristics and minor allele frequencies were compared between BPD-PH (cases) and BPD-without PH (control) groups. Biomarker models to predict PH in BPD using clinical and SNP data were tested by calculations of area under the ROC curve. In our BPD cohort, 32% (n = 61) had PH. Of the DUSP SNPs evaluated, DUSP1 SNP rs322351 was less common, and DUSP5 SNPs rs1042606 and rs3793892 were more common in cases than in controls. The best fit biomarker model combines clinical and DUSP genetic data with an area under the ROC curve of 0.76. We identified three DUSP SNPs as potential BPD-PH biomarkers. Combining clinical and DUSP genetic data yields the most robust predictor for PH in BPD.


  • Open Access

    DDAH1 regulates apoptosis and angiogenesis in human fetal pulmonary microvascular endothelial cells

    by Jennifer K. Trittmann, Hanadi Almazroue, Yi Jin, Leif D. Nelin

    Nitric Oxide (NO) is an endogenous pulmonary vasodilator produced by endothelial NO synthase (eNOS). Asymmetric dimethyl L‐arginine (ADMA) is an endogenous inhibitor of eNOS activity. In endothelial cells, ADMA is hydrolyzed to L‐citrulline primarily by dimethylarginine dimethyl‐aminohydrolase‐1 (DDAH1). We tested the hypothesis that DDAH1 expression is essential for maintaining NO production in human fetal pulmonary microvascular endothelial cells (hfPMVEC), such that knockdown of DDAH1 expression will lead to decreased NO production resulting in less caspase‐3 activation and less tube formation. We found that hfPMVEC transfected with DDAH1 siRNA had lower NO production than control, with no difference in eNOS protein levels between groups. hfPMVEC transfected with DDAH1 siRNA had lower protein levels of cleaved caspase‐3 and ‐8 than control. Both DDAH1 siRNA‐ and ADMA‐treated hfPMVEC had greater numbers of viable cells than controls. Angiogenesis was assessed using tube formation assays in matrigel, and tube formation was lower after either DDAH1 siRNA transfection or ADMA treatment than controls. Addition of an NO donor restored cleaved caspase‐3 and ‐8 protein levels after DDAH1 siRNA transfection in hfPMVEC to essentially the levels seen in scramble control. Addition of a putative caspase‐3 inhibitor to DDAH1 siRNA transfected and NO‐donor treated cells led to greater numbers of viable cells and far less angiogenesis than in any other group studied. We conclude that in hfPMVEC, DDAH1 is central to the regulation of NO‐mediated caspase‐3 activation and the resultant apoptosis and angiogenesis. Our findings suggest that DDAH1 may be a potential therapeutic target in pulmonary hypertensive disorders.


  • Open Access

    Hypoxic Pulmonary Endothelial Cells Release Epidermal Growth Factor which Results in Vascular Smooth Muscle Cell Arginase 2 Expression and Proliferation

    by Caitlyn M Pool, Yi Jin, Jennifer K Trittmann, Bernadette Chen, Yusen Liu, Leif D Nelin

    The hallmark of pulmonary hypertension (PH) is vascular remodeling leading to alterations in hemodynamics and vasoreactivity. Endothelial cells (EC) are central in the response of a vessel to stimuli associated with PH. EC can proliferate contributing to vascular remodeling, but likely a more important role of EC is the release of factors that induce proliferation in the underlying smooth muscle cells (SMC) leading to intimal thickening. Hypoxia is associated with the development of PH in certain human diseases. We have previously shown that human pulmonary microvascular EC (hPMVEC) respond to hypoxia with proliferation that is dependent on arginase 2 up‐regulation. This arginase 2 up‐regulation is mediated by the release of epidermal growth factor (EGF) and resultant activation of EGF receptors (EGFR) on hPMVEC. We hypothesized that the release of EGF by hPMVEC would also result in proliferation of human pulmonary arterial SMC (hPASMC) via EGFR‐mediated arginase 2 up‐regulation. To test this hypothesis, we used conditioned media (CM) from hPMVEC grown either in normoxia or hypoxia to study the role of EGF released by hPMVEC on the regulation of arginase 2 and proliferation in hPASMC. When hPASMC were grown with CM from hypoxic hPMVEC there was a 9‐fold induction of arginase 2 protein levels and more than a doubling of viable hPASMC numbers compared to hPASMC grown with CM from normoxic hPMVEC. In another experiment, hPVMEC were transfected with a scramble siRNA (scramble) or an siRNA against EGF (siEGF) and then the hPMVEC placed in hypoxia to generate conditioned media. In the hPASMC treated with the CM from siEGF‐treated hypoxic hPMVEC there were lower levels of arginase 2 protein than in the hPASMC grown in CM from hPMVEC grown in normoxia; and substantially less arginase 2 than in hPASMC treated with CM from hypoxic hPMVEC treated with scramble. Furthermore, hPASMC treated with hypoxic CM from siEGF‐treated hPMVEC had substantially lower viable cell numbers than in hPASMC treated with hypoxic CM from scramble‐treated hPMVEC. When hPASMC were treated with hypoxic CM from hPMVEC the addition of an EGF neutralizing antibody to the CM prevented the increase in viable cell numbers seen with hypoxic CM. When hPASMC were transfected with siRNA against EGFR and then treated with hypoxic CM from hPMVEC the hypoxia‐induced increase in arginase 2 protein levels and viable cell numbers were prevented. These data demonstrate that hPMVEC release EGF, which can activate EGFR on hPASMC to induce arginase 2 protein expression and increase viable cell numbers. We speculate that EGF neutralizing antibodies or EGFR blocking antibodies are potential therapeutics to prevent and/or attenuate the vascular remodeling seen in PH associated with hypoxia. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .


  • Using clinical and genetic data to predict pulmonary hypertension in bronchopulmonary dysplasia

    by J K Trittmann, A Bartenschlag, E J Zmuda, J Frick, W C L Stewart, L D Nelin

    Aim: Pulmonary hypertension significantly increases morbidity and mortality in infants with bronchopulmonary dysplasia. The frequency of single nucleotide polymorphisms in arginase‐1 (ARG1 rs2781666) and dimethylarginine dimethylaminohydrolase‐1 (DDAH1 rs480414) genes has been found to differ in a cohort of bronchopulmonary dysplasia patients with pulmonary hypertension (cases) and without pulmonary hypertension (controls). Therefore, we tested the hypothesis that combining these genotypes with phenotypic data would better predict pulmonary hypertension in bronchopulmonary dysplasia patients.Methods: Bronchopulmonary dysplasia patients (n = 79) born at <35 weeks gestation were studied. Pulmonary hypertension was diagnosed by echocardiographic criteria (n = 20). ROC curves to predict pulmonary hypertension in bronchopulmonary dysplasia were generated from genotype and/or clinical data.Results: Cases were born at an earlier gestation and weighed less at birth than did controls. ROC curves for rs2781666 had an AUC of 0.61, while rs480414 had an AUC of 0.66. Together, the AUC was 0.70. When clinical data were added to the genetic model, AUC was 0.73.Conclusion: These findings demonstrate that ROC predictive modelling of pulmonary hypertension in bronchopulmonary dysplasia improves with inclusion of both genotypic and phenotypic data. Further refinement of these types of models could facilitate the implementation of precision medicine approaches to pulmonary hypertension in bronchopulmonary dysplasia.